Table 5. Low-stage and high-stage disease evaluated separately.
Percentage of 5-year DSS and p-value for each group.
| Low-stage | High-stage | ||||||
|---|---|---|---|---|---|---|---|
| No. of cases (%) | DSS % | HR (CI) p | No. of cases (%) | DSS % | HR (CI) p | ||
| T old classification | T1 | 58 (80.6) | 79.2 | 0.411 (0.053–3.215) p = 0.260 | 32 (57.1) | 45.2 | 0.887 (0.554–1.4174) p = 0.591 |
| T2 | 14 (19.4) | 90.9 | 14 (25.0) | 45.5 | |||
| T3 | ÷ | ÷ | 8 (14.3) | 66.7 | |||
| T4 | ÷ | ÷ | 2 (3.6)) | 50.0 | |||
| T 8 ed classification | T1 | 42 (54.5) | 91.2 | 3.344 (0.886–12.616) p = 0.035 | 5 (8,8) | 25.0 | 0.732 (0.425–1.266) p = 0.210 |
| T2 | 35 (45.5) | 73.3 | 18 (31.6) | 35.3 | |||
| T3 | ÷ | ÷ | 34 (59.6) | 58.6 | |||
| N | N0 | 77 (100) | 87.5 | ÷ | 23 (36.5) | 70.0 | 2.862 (1.167–7.020) p = 0.021 |
| N+ | ÷ | ÷ | 40 (63.5) | 30.6 | |||
| TB 2-tier | Low (Bd1) | 65 (86.7) | 86.8 | 2.872 (0.742–11.121) p = 0.089 | 43 (72.9) | 48.6 | 1.305 (0.558–2.894) p = 0.496 |
| High (Bd2+Bd3) | 10 (13.3) | 66.7 | 16 (27.1) | 40.0 | |||
| TB 3-tier | Bd1 <5 | 65 (86.7) | 86.8 | 1.875 (0.784–4.489) p = 0.091 | 43 (72.9) | 48.6 | 1.427 (0.890–2.290) p = 0.094 |
| Bd2 ≥5 and<10 | 7 (9.3) | 66.7 | 8 (13.6) | 71.4 | |||
| Bd3 ≥ 10 | 3 (4.0) | 66.7 | 8 (13.6) | 12.5 | |||
| DOI 2-tier | < 4 mm | 25 (33.8) | 94.4 | 4.415 (0.565–34.505) p = 0.098 | 3 (5.3) | 0.0 | 0.461 (0.138–1.545) p = 0.016 |
| ≥4 mm | 49 (66.2) | 76.7 | 54 (94.7) | 51.1 | |||
| DOI 3-tier | < 5 mm | 41 (53.2) | 90.9 | 3.513 (0.931–13.256) p = 0.043 | 5 (8.8) | 25.0 | 0.686 (0.400–1.175) p = 0.119 |
| ≥5 mm and<10 mm | 33 (44.6) | 71.4 | 19 (33.3) | 33.3 | |||
| ≥10 mm | 0 | ÷ | 33 (57.9) | 60.7 | |||
| Combined TB/DOI*-score | TB/DOI-0 | 21 (28.8) | 100 | 2.797 (0.997–7.843) p = 0.005 | 2 (3.4) | 0.0 | 0.843 (0.388–1.833) p = 0.609 |
| TB/DOI-1 | 45 (61.6) | 77.5 | 44 (74.6) | 50.0 | |||
| TB/DOI-2 | 7 (9.6) | 66.7 | 13 (22.0) | 50.0 | |||